公开(公告)号：US09969798B2

公开(公告)日：2018-05-15

申请号：US15072811

申请日：2016-03-17

Applicant: ABBVIE STEMCENTRX LLC

Inventor： Johannes Hampl ,  Scott J. Dylla ,  Orit Foord ,  Robert A. Stull

IPC: C07K16/18 ,  A61K47/64 ,  A61K47/68 ,  C07K16/28 ,  G01N33/574 ,  C07K16/40 ,  C07K16/30 ,  A61K38/47

CPC classification number: C07K16/18 ,  A61K38/47 ,  A61K47/64 ,  A61K47/6455 ,  A61K47/6811 ,  A61K47/6815 ,  A61K47/6855 ,  A61K47/6867 ,  A61K47/6869 ,  A61K47/6891 ,  C07K16/28 ,  C07K16/2809 ,  C07K16/2896 ,  C07K16/30 ,  C07K16/3015 ,  C07K16/3061 ,  C07K16/3069 ,  C07K16/40 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C12Y302/02022 ,  G01N33/574

Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of such modulators to treat hyperproliferative disorders are provided.

公开(公告)号：US09689862B2

公开(公告)日：2017-06-27

申请号：US14355986

申请日：2012-11-05

Applicant: PIERRE FABRE MEDICAMENT

Inventor： Charlotte Beau-Larvor ,  Liliane Goetsch ,  Nicolas Boute

IPC: C07K16/28 ,  C07K16/30 ,  G01N33/50 ,  C07K14/71 ,  C07K16/32 ,  A61K47/48 ,  G01N33/68 ,  A61K38/47 ,  C07K16/18 ,  C12N9/24 ,  A61K39/00

CPC classification number: G01N33/5035 ,  A61K38/47 ,  A61K47/6843 ,  A61K47/6851 ,  A61K2039/505 ,  C07K14/71 ,  C07K16/18 ,  C07K16/2803 ,  C07K16/30 ,  C07K16/32 ,  C07K2317/14 ,  C07K2317/20 ,  C07K2317/33 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2319/30 ,  C07K2319/74 ,  C12N9/2497 ,  C12Y302/02022 ,  G01N33/6854 ,  G01N2333/912 ,  G01N2500/04 ,  G01N2500/10

Abstract: The present invention relates to an antigen binding protein, in particular a monoclonal antibody, capable of binding specifically to the protein Axl as well as the amino and nucleic acid sequences coding for said protein. From one aspect, the invention relates to an antigen binding protein, or antigen binding fragments, capable of binding specifically to Axl and, by inducing internalization of Axl, being internalized into the cell. The invention also comprises the use of said antigen binding protein as an addressing product in conjugation with other anti-cancer compounds, such as toxins, radio-elements or drugs, and the use of same for the treatment of certain cancers.

公开(公告)号：US09266946B2

公开(公告)日：2016-02-23

申请号：US14251932

申请日：2014-04-14

Applicant: The Brigham and Women's Hospital, Inc.

Inventor： Markus H. Frank ,  Natasha Y. Frank ,  Mohamed H. Sayegh

IPC: A61K39/395 ,  C07K16/18 ,  A61K39/00

CPC classification number: A61K47/6851 ,  A61K31/713 ,  A61K38/47 ,  A61K2039/505 ,  C07K16/18 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/734 ,  C12N15/1135 ,  C12N2310/14 ,  C12N2310/3513 ,  C12N2320/32 ,  C12Y302/02022 ,  G01N33/57492 ,  G01N2333/705

Abstract: The invention relates to methods for treating a subject by manipulating ABCB5 on a cell as well as related products. The methods include methods of treating cancer using ABCB5 binding molecules such as antibodies and fragments thereof.

Abstract translation: 本发明涉及通过操作细胞上的ABCB5以及相关产品来治疗受试者的方法。 所述方法包括使用ABCB5结合分子（例如抗体及其片段）治疗癌症的方法。

公开(公告)号：US10004812B2

公开(公告)日：2018-06-26

申请号：US15116419

申请日：2015-02-04

Applicant: Oncomatryx Biopharma, S.L.

Inventor： Roland Kontermann ,  Klaus Pfizenmaier ,  Cristina Ferrer ,  Myriam Fabre ,  Laureano Simon

IPC: A61K39/395 ,  A61K47/48 ,  C07K16/28 ,  A61K45/06 ,  C07K16/30 ,  C12N9/24 ,  C12N9/96 ,  A61K47/65 ,  A61K47/60 ,  A61K47/68 ,  A61K39/00

CPC classification number: A61K47/6849 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/60 ,  A61K47/65 ,  A61K47/6803 ,  A61K2039/505 ,  C07K16/2896 ,  C07K16/30 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/71 ,  C07K2317/77 ,  C12N9/2497 ,  C12N9/96 ,  C12Y302/02022

Abstract: The present invention relates to conjugates, in particular antibody-drug conjugates and immunotoxins, having the formula I: A-(L-D)p (I) or a pharmaceutically acceptable salts or solvates thereof, wherein: A is an antibody that selectively binds Endoglin; L is a linker; D is a drug comprising a cytolysin or a Nigrin-b A-chain; and p is 1 to 10, and to use of such conjugates in the therapeutic treatment of tumors. Methods of producing such conjugates and components for use in such methods are disclosed.

公开(公告)号：US20170232115A1

公开(公告)日：2017-08-17

申请号：US15380962

申请日：2016-12-15

Applicant: STC.UNM ,  Sandia Corporation

Inventor： Carlee Erin Ashley ,  C. Jeffrey Brinker ,  Eric C. Carnes ,  Mohammed Houman Fekrazad ,  Linda A. Felton ,  Oscar Negrete ,  David Patrick Padilla ,  Brian S. Wilkinson ,  Dan C. Wilkinson ,  Cheryl L. Willman

IPC: A61K49/00 ,  A61K33/24 ,  A61K31/513 ,  C12N15/113 ,  A61K38/45 ,  A61K31/506 ,  A61K38/47 ,  A61K31/465 ,  A61K31/192 ,  A61K31/704 ,  A61K48/00

CPC classification number: A61K48/0008 ,  A61K9/0014 ,  A61K9/107 ,  A61K9/1271 ,  A61K9/5078 ,  A61K31/192 ,  A61K31/465 ,  A61K31/506 ,  A61K31/513 ,  A61K31/704 ,  A61K31/7088 ,  A61K31/7105 ,  A61K31/713 ,  A61K33/24 ,  A61K38/00 ,  A61K38/17 ,  A61K38/45 ,  A61K38/47 ,  A61K45/06 ,  A61K47/6923 ,  A61K49/0082 ,  A61K49/0423 ,  B82Y5/00 ,  C07K7/06 ,  C07K2319/00 ,  C12N15/113 ,  C12N15/1131 ,  C12N15/88 ,  C12N2310/14 ,  C12N2320/32 ,  C12N2810/40 ,  C12Y204/02036 ,  C12Y302/02022 ,  A61K2300/00

Abstract: The present invention is directed to protocells for specific targeting of hepatocellular and other cancer cells which comprise a nanoporous silica core with a supported lipid bilayer; at least one agent which facilitates cancer cell death (such as a traditional small molecule, a macromolecular cargo (e.g. siRNA or a protein toxin such as ricin toxin A-chain or diphtheria toxin A-chain) and/or a histone-packaged plasmid DNA disposed within the nanoporous silica core (preferably supercoiled in order to more efficiently package the DNA into protocells) which is optionally modified with a nuclear localization sequence to assist in localizing protocells within the nucleus of the cancer cell and the ability to express peptides involved in therapy (apoptosis/cell death) of the cancer cell or as a reporter, a targeting peptide which targets cancer cells in tissue to be treated such that binding of the protocell to the targeted cells is specific and enhanced and a fusogenic peptide that promotes endosomal escape of protocells and encapsulated DNA. Protocells according to the present invention may be used to treat cancer, especially including hepatocellular (liver) cancer using novel binding peptides (c-MET peptides) which selectively bind to hepatocellular tissue or to function in diagnosis of cancer, including cancer treatment and drug discovery.

公开(公告)号：US20160136297A1

公开(公告)日：2016-05-19

申请号：US15005364

申请日：2016-01-25

Applicant: The Brigham and Women's Hospital, Inc

Inventor： Markus H. Frank ,  Natasha Y. Frank ,  Mohamed H. Sayegh

IPC: A61K47/48 ,  G01N33/574 ,  C12N15/113 ,  A61K38/47 ,  A61K31/713

CPC classification number: A61K47/6851 ,  A61K31/713 ,  A61K38/47 ,  A61K2039/505 ,  C07K16/18 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/734 ,  C12N15/1135 ,  C12N2310/14 ,  C12N2310/3513 ,  C12N2320/32 ,  C12Y302/02022 ,  G01N33/57492 ,  G01N2333/705

Abstract: The invention relates to methods for treating a subject by manipulating ABCB5 on a cell as well as related products. The methods include methods of treating cancer using ABCB5 binding molecules such as antibodies and fragments thereof.

公开(公告)号：US20160131639A1

公开(公告)日：2016-05-12

申请号：US14855696

申请日：2015-09-16

Applicant: PIERRE FABRE MEDICAMENT

Inventor： Charlotte Beau-Larvor ,  Liliane Goetsch

IPC: G01N33/50 ,  C12N9/24 ,  A61K38/47 ,  C07K16/18 ,  A61K47/48

CPC classification number: G01N33/5035 ,  A61K38/47 ,  A61K47/6843 ,  A61K47/6851 ,  A61K2039/505 ,  C07K14/71 ,  C07K16/18 ,  C07K16/2803 ,  C07K16/30 ,  C07K16/32 ,  C07K2317/14 ,  C07K2317/20 ,  C07K2317/33 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2319/30 ,  C07K2319/74 ,  C12N9/2497 ,  C12Y302/02022 ,  G01N33/6854 ,  G01N2333/912 ,  G01N2500/04 ,  G01N2500/10

Abstract: The present invention relates to a novel antigen binding protein, in particular a monoclonal antibody, capable of binding specifically to the protein Axl as well as the amino and nucleic acid sequences coding for said protein. From one aspect, the invention relates to a novel antigen binding protein, or antigen binding fragments, capable of binding specifically to Axl and, by inducing internalization of Axl, being internalized into the cell. The invention also comprises the use of said antigen binding protein as an addressing product in conjugation with other anti-cancer compounds, such as toxins, radio-elements or drugs, and the use of same for the treatment of certain cancers.

Abstract translation: 本发明涉及能够特异性结合蛋白质Ax1以及编码所述蛋白质的氨基酸和核酸序列的新型抗原结合蛋白，特别是单克隆抗体。 从一方面，本发明涉及能够特异性结合Ax1并通过诱导将内源化的Ax1内化到细胞中的新型抗原结合蛋白或抗原结合片段。 本发明还包括使用所述抗原结合蛋白作为与其它抗癌化合物如毒素，放射性元件或药物共轭的寻址产物，以及其用于治疗某些癌症的用途。

公开(公告)号：US20160068829A1

公开(公告)日：2016-03-10

申请号：US14845013

申请日：2015-09-03

Applicant: VALIANT BIOPHARMA SDN BHD

Inventor： Muhammad Sagaf ABU BAKAR, Ag. ,  Eng Huan UNG

IPC: C12N9/24 ,  C07K14/47

CPC classification number: C12N9/2497 ,  A61K38/00 ,  A61K38/1709 ,  C07K14/4723 ,  C07K2319/00 ,  C12Y302/02022

Abstract: A fusion protein comprising at least one Type 1 Ribosome Inactivating Protein, polypeptide B; and at least one polypeptide A capable of viral entry inhibition; and/or at least one Cationic AntiMicrobial Peptide, polypeptide C.

公开(公告)号：US20160030529A1

公开(公告)日：2016-02-04

申请号：US14775049

申请日：2014-03-13

Applicant: EMORY UNIVERSITY

Inventor： John S LOLLAR ,  John F HEALEY

IPC: A61K38/47 ,  A61K38/37 ,  C12N9/24 ,  C07K14/755

CPC classification number: A61K38/47 ,  A61K38/164 ,  A61K38/168 ,  A61K38/37 ,  C07K14/755 ,  C07K2319/55 ,  C12N9/2497 ,  C12Y302/02022 ,  A61K2300/00

Abstract: This disclosure relates to composition and methods for improving blood clotting in a subject that developed anti-factor VIII antibodies. In certain embodiments, this disclosure contemplates a conjugate comprising a toxin, e.g., ricin, abrin, saporin, coupled to factor VIII or functional variant thereof either through a linking group or as a fusion protein.

Abstract translation: 本公开涉及用于改善开发抗因子VIII抗体的受试者中的血液凝固的组合物和方法。 在某些实施方案中，本公开涉及包含通过连接基团或融合蛋白偶联至因子VIII或其功能变体的毒素，例如蓖麻毒素，相思豆毒素，皂草素的缀合物。

公开(公告)号：US09173962B2

公开(公告)日：2015-11-03

申请号：US13935918

申请日：2013-07-05

Applicant: Charlotte Beau-Larvor ,  Liliane Goetsch ,  Nicolas Boute

Inventor： Charlotte Beau-Larvor ,  Liliane Goetsch ,  Nicolas Boute

IPC: G01N33/53 ,  A61K47/48 ,  C07K14/71 ,  C07K16/28 ,  C07K16/32 ,  C07K16/30 ,  G01N33/68 ,  A61K39/00

CPC classification number: G01N33/5035 ,  A61K38/47 ,  A61K47/6843 ,  A61K47/6851 ,  A61K2039/505 ,  C07K14/71 ,  C07K16/18 ,  C07K16/2803 ,  C07K16/30 ,  C07K16/32 ,  C07K2317/14 ,  C07K2317/20 ,  C07K2317/33 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2319/30 ,  C07K2319/74 ,  C12N9/2497 ,  C12Y302/02022 ,  G01N33/6854 ,  G01N2333/912 ,  G01N2500/04 ,  G01N2500/10

Abstract: The present invention relates to a novel antigen binding protein, in particular a monoclonal antibody, capable of binding specifically to the protein Axl as well as the amino and nucleic acid sequences coding for said protein. From one aspect, the invention relates to a novel antigen binding protein, or antigen binding fragments, capable of binding specifically to Axl and, by inducing internalization of Axl, being internalized into the cell. The invention also comprises the use of said antigen binding protein as an addressing product in conjugation with other anti-cancer compounds, such as toxins, radio-elements or drugs, and the use of same for the treatment of certain cancers.

Abstract translation: 本发明涉及能够特异性结合蛋白质Ax1以及编码所述蛋白质的氨基酸和核酸序列的新型抗原结合蛋白，特别是单克隆抗体。 从一方面，本发明涉及能够特异性结合Ax1并通过诱导将内源化的Ax1内化到细胞中的新型抗原结合蛋白或抗原结合片段。 本发明还包括使用所述抗原结合蛋白作为与其它抗癌化合物如毒素，放射性元件或药物共轭的寻址产物，以及其用于治疗某些癌症的用途。